Industry Leader articles are written by executives at biopharma companies, consultancies, research firms, and companies that provide services or products to sponsors. The topics are nonpromotional and focused on industrywide business issues.
How To Overcome Bottlenecks To Expedite Drug Approvals
For most drug developers, the question remains: How can we accelerate delivering new drugs to patients, while at the same time, ensuring those drugs meet stringent regulatory requirements? Here are some tips that may help.
Virtual Marking: A Flexible Option For Pharmaceuticals
Although virtual marking has been available for nearly a decade, courts have provided little specific guidance. Still, there are some points to keep in mind for virtual marking.
Realizing The Value Of Quantum Computing In Life Sciences
In the life sciences sector, quantum computing holds great potential for transforming data-heavy processes, from accelerating drug discovery to simulating clinical trials, and is one of the key technological areas we predict will impact life sciences for the better.
How To Prepare For The Next Healthcare Crisis That We Don’t See Coming
Given everything that we have learned from the COVID-19 situation, healthcare leaders can implement the following key takeaways to help them successfully weather the next storm that comes our way.
Do Biobanks Need New Strategies?
Precision medicine necessitates precision research, which necessitates getting highly specific biospecimens to researchers on demand, in alignment with their demand. Researchers shouldn’t have to adjust their research to whatever specimens are available; supply needs to fit the research.
Building A Legacy With Complex Assets
For life science executives, deciding how to manage your overall portfolio, including illiquid or complex assets, is an important step in preserving both your financial and philanthropic legacies.
How We Landed In The International Space Station
Looking back, it’s ironic that we named our company LaunchPad Medical. Our inspiration for the name came from our plan to take challenging ideas and materials and “launch” them into the medical space to revolutionize healthcare. But it never dawned on me to take our research to the International Space Station (ISS).
Taking A Strengths-Based Approach To Diversity & Inclusion
Organizations and their leaders often focus on what needs to improve, but research shows there is more to be gained from a strengths-based approach. Coaching around strengths yields greater optimism and success.
6 Tips For Contracting Or Seeking Funding From The Federal Government
With the right preparation and investments, entering the federal government market can lead to considerable growth and visibility for your company. Consider the following tips for increased chances of success.
The Great Regulatory Catch-Up: Shortcuts To Compliance For Medical Devices Manufacturers
The medical device market is about to succumb to a raft of substantial international regulatory changes, starting with Europe’s MDR in May 2020, as public pressure and industry authorities call for greater accountability for patient safety.
BEYOND THE PRINTED PAGE
How We Have Changed For The Better Thanks To COVID-195/17/2021
An interview with Mei Mei Hu, cofounder and CEO of Vaxxinity, provides an example of how COVID-19 and Zoom have enabled the seeing and showing of one another’s humanness.
Communicating Authentically During Times Of Crisis4/19/2021
John Fowler, cofounder and CEO of Kezar Life Sciences, shares “A Letter to Kezar Employees,” a best practice example of a leader communicating authentically and transparently during times of crisis (i.e., the killing of George Floyd).
A Lesson Learned The Hard Way4/18/2021
Neil Kumar, cofounder and CEO of BridgeBio, discusses his rationale behind why employees didn’t have titles during the startup phase.
LIFE SCIENCE LEADER BLOGS
Disruption of life routines by COVID-19 provide a CNS opportunity on multiple fronts.
While biopharma's response to COVID-19 has started to turnaround the industry's sagging reputation, one successful response to one crisis does not a reputation save.